Complete Conference Management 8th Annual Symposium Contemporary Management of Cardiovascular Disease in Women 2025

This educational symposium will review the current epidemiology of cardiovascular disease in women, and examine women– specific cardiovascular issues related to diagnosis and treatment. Cardiovascular risk factors, hormone replacement therapy, and management of CAD and valvular heart disease during pregnancy will be examined. In addition, current updates on lipid therapies, risk assessment and venous insufficiency will be discussed. Sex specific differences in the management of congestive heart failure, atrial fibrillation, amyloidosis and hypertrophic obstructive cardiomyopathy will be reviewed. State of the art invasive, percutaneous therapies for aortic diseases, valvular heart disease, resistant hypertension, and CAD will be included, with an emphasis on gender-specific outcomes. This year will include updates for ASCVD risk assessment and FDA-approved medication for cardiovascular-kidney-metabolic (CKM) syndrome. Finally, cased-based presentations will highlight ongoing dilemmas in cardiovascular management, including the use of novel pharmaceutical agents and invasive techniques.
MAIN OBJECTIVE
The objective of this symposium is to educate healthcare providers on gender-specific approaches in prevention, diagnosis, and treatment of women with a broad range of cardiovascular diseases.
OVERALL OBJECTIVES
1. Review and understand the current epidemiology of cardiovascular disease in women.
2. Educate the practitioner on cardiovascular disease risk factors and diseases more common in women that are often overlooked.
3. Review the current guidelines for the management of cardiovascular disease, congestive heart failure, valvular heart disease, atrial fibrillation, and aortic disease with an emphasis on sex specific outcomes and recommendations.
NEEDS ASSESSMENT
Heart disease is the leading cause of death in women in the US and accounts for more deaths each year than all other causes combined. The rates of death are even higher in women of racial or ethnic minority. One in three women will die of some form of heart or vascular disease. However, only one-third of women are aware of this statistic and only half would call 911 if they had symptoms of a heart attack. Compared to men, women are less likely to receive standard of care of treatment for chest pain, less likely to be referred to a cardiologist, and less likely to be admitted to the hospital. It is our mission to reduce sex-based disparities and achieve equity in cardiovascular care by educating healthcare providers about the impact of cardiovascular disease on women and empowering them to be advocates for women’s cardiovascular health.
TARGET AUDIENCE
This program has been designed to provide primary care physicians, internists, cardiologists, nurse practitioners, physician assistants, nurses, pharmacists and other healthcare providers with the necessary information to increase knowledge and awareness of cardiovascular disease in women with the goal of improving patient care.
 
+ Topics:

7:00 Registration Opens
7:30am Breakfast Served
7:30-8:30am Product Theatre (Non-CME) Coronary Artery Disease in Women: Utilizing CCTA to Inform & Guide Treatment Decisions Speakers: Malissa Wood, MD and Arash Nayeri, MD Sponsored by: Heartflow
8:40-8:45 Welcome and Introductory Remarks Christina Economides, MD, MM, FSCAI
8:45-9:05 Updates in Medical Therapy for Heart Failure Michelle Kittleson, MD, PhD
9:05-9:25 Cardiovascular Disease in Women: 2025 Update Christina Economides, MD, MM, FSCAI
9:25-9:45 Novel Lipid Lowering Agents: Current Recommendations Karol Watson, MD, PhD
9:45-10:05 Hormone Replacement Therapy and Risk of Cardiovascular Disease Janet Wei, MD, FACC
10:05-10:20 Question & Answer
10:20-10:35 Break
10:35-10:55 Aortic Diseases in Women: Diagnosis and Treatment Guy Mayeda, MD
10:55-11:15 Atrial Fibrillation Ablation in Women Anil Bhandari, MD
11:15-11:35 The TAVR Gender Paradox Nichelle Megowan, MD
11:35-11:55 Sex Differences in Percutaneous Repair of Mitral and Tricuspid Valves Steven Burstein, MD
11:55-12:10 Question & Answer
12:20-1:20 Product Theatre Luncheon (Non-CME) Transthyretin Cardiac Amyloidosis/ATTR-CM in Women: A Call to Action for Cardiologists Speaker: Vivian Navas, MD Sponsored by: Pfizer
1:30-1:50 Managing CAD and CAD Risk Factors During Pregnancy Priya Pillutla, MD
1:50-2:10 Therapeutic Options for Valvular Heart Disease in Young Women Uri Elkayam, MD
2:10-2:30 Diagnosis and Treatment of Cardiac Amyloidosis in Women Joseph Rahman, MD
2:30-2:50 Diagnosis and Management of Hypertrophic Cardiomyopathy in Women Katrine Zhiroff, MD
 2:50-3:05 Question & Answer
3:05-3:20 Break
3:20-3:30 Management of Chronic Venous Insufficiency Jessica Weiss, DO
3:30-3:40 Primary Prevention of ASCVD and Risk Assessment in Women Katrine Zhiroff, MD
3:40-4:35 Clinical Vignettes: Management of CAD and Heart Failure in Women

Finerenone and Semaglutide for the Treatment of Cardiovascular-Kidney-Metabolic (CKM) Syndrome
Renal Denervation for Resistant Hypertension
Barostim for HFrEF
Intravascular Lithotripsy for Calcified CAD in Women
Mechanical Circulatory Support for High-Risk PCI
Moderators: Christina Economides, MD, MM, FSCAI Katrine Zhiroff, MD, FACC, FSCAI

4:35-4:50 Question & Answer
4:50-5:05 Closing Remarks
5:05 Adjourn